Targeted therapy for chronic lymphocytic leukemia : Hematological malignancy: coordinated by J. O. ArmitageQUINTAS-CARDAMA, Alfonso; O'BRIEN, Susan.Targeted oncology. 2009, Vol 4, Num 1, pp 11-21, issn 1776-2596, 11 p.Article

AlemtuzumabRAVANDI, Farhad; O'BRIEN, Susan.Expert review of anticancer therapy. 2005, Vol 5, Num 1, pp 39-51, issn 1473-7140, 13 p.Article

Chronic lymphoid leukemias other than chronic lymphocytic leukemia : Diagnosis and treatmentRAVANDI, Farhad; O'BRIEN, Susan.Mayo Clinic proceedings. 2005, Vol 80, Num 12, pp 1660-1674, issn 0025-6196, 15 p.Article

Hatch size, somatic growth rate and size-dependent survival in the endangered ploughshare tortoiseO'BRIEN, Susan; ROBERT, Bourou; TIANDRAY, Hafany et al.Biological conservation. 2005, Vol 126, Num 2, pp 141-145, issn 0006-3207, 5 p.Article

High-dose rituximab therapy in chronic lymphocytic leukemiaKEATING, Michael; O'BRIEN, Susan.Seminars in oncology. 2000, Vol 27, Num 6, pp 86-90, issn 0093-7754, SUP12Conference Paper

Investigational Immunotherapeutics for B-Cell MalignanciesQUINTAS-CARDAMA, Alfonso; WIERDA, William; O'BRIEN, Susan et al.Journal of clinical oncology. 2010, Vol 28, Num 5, pp 884-892, issn 0732-183X, 9 p.Article

Chronic lymphocytic leukemia : Diagnosis and treatmentYEE, Karen W. L; O'BRIEN, Susan M.Mayo Clinic proceedings. 2006, Vol 81, Num 8, pp 1105-1129, issn 0025-6196, 25 p.Article

Hot water treatments for the control of rots on harvested litchi (Litchi chinensis Sonn.) fruitOLESEN, Trevor; NACEY, Lakshmi; WILTSHIRE, Neil et al.Postharvest biology and technology. 2004, Vol 32, Num 2, pp 135-146, issn 0925-5214, 12 p.Article

Methadone and breastfeeding: New horizonsPHILIPP, Barbara L; MEREWOOD, Anne; O'BRIEN, Susan et al.Pediatrics (Evanston). 2003, Vol 111, Num 6, pp 1429-1430, issn 0031-4005, 2 p., 1Article

Gemtuzumab ozogamicin in the treatment of acute myeloid leukemiaGILES, Francis; ESTEY, Elihu; O'BRIEN, Susan et al.Cancer. 2003, Vol 98, Num 10, pp 2095-2104, issn 0008-543X, 10 p.Article

Consequences of violating the recapture duration assumption of mark-recapture models : a test using simulated and empirical data from an endangered tortoise populationO'BRIEN, Susan; ROBERT, Bourou; TIANDRY, Hafany et al.Journal of applied ecology. 2005, Vol 42, Num 6, pp 1096-1104, issn 0021-8901, 9 p.Article

Targeted Therapies in Hematology and Their Impact on Patient Care: Chronic and Acute Myeloid LeukemiaJABBOUR, Elias; CORTES, Jorge; RAVANDI, Farhad et al.Seminars in hematology. 2013, Vol 50, Num 4, pp 271-283, issn 0037-1963, 13 p.Article

Monoclonal Antibody-Based Therapies: A New Dawn in the Treatment of Acute Lymphoblastic LeukemiaKANTARJIAN, Hagop; THOMAS, Deborah; WAYNE, Alan S et al.Journal of clinical oncology. 2012, Vol 30, Num 31, pp 3876-3883, issn 0732-183X, 8 p.Article

Emerging information on the use of rituximab in chronic lymphocytic leukemiaKEATING, Michael J; O'BRIEN, Susan; ALBITAR, Maher et al.Seminars in oncology. 2002, Vol 29, Num 1, pp 70-74, issn 0093-7754, SUP2Article

Nocardia veterana bloodstream infection in a patient with cancer and a summary of reported casesANSARI, Shoaib R; SAFDAR, Amar; HAN, Xiang Y et al.International journal of infectious diseases. 2006, Vol 10, Num 6, pp 483-486, issn 1201-9712, 4 p.Article

Treatment of chronic lymphocytic leukemiaFERRAJOLI, Alessandra; O'BRIEN, Susan M.Seminars in oncology. 2004, Vol 31, Num 2, pp 60-65, issn 0093-7754, 6 p., SUP4Conference Paper

Results of Inotuzumab Ozogamicin, a CD22 Monoclonal Antibody, in Refractory and Relapsed Acute Lymphocytic LeukemiaKANTARJIAN, Hagop; THOMAS, Deborah; FADERL, Stefan et al.Cancer. 2013, Vol 119, Num 15, pp 2728-2736, issn 0008-543X, 9 p.Article

Elacytarabine has single-agent activity in patients with advanced acute myeloid leukaemiaO'BRIEN, Susan; RIZZIERI, David A; STAUDACHER, Karin et al.British journal of haematology. 2012, Vol 158, Num 5, pp 581-588, issn 0007-1048, 8 p.Article

The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivoPONADER, Sabine; CHEN, Shih-Shih; BUGGY, Joseph J et al.Blood. 2012, Vol 119, Num 5, pp 1182-1189, issn 0006-4971, 8 p.Article

Current Event-Free Survival After Sequential Tyrosine Kinase Inhibitor Therapy for Chronic Myeloid LeukemiaAL-KALI, Aref; KANTARJIAN, Hagop; JIANQIN SHAN et al.Cancer. 2011, Vol 117, Num 2, pp 327-335, issn 0008-543X, 9 p.Article

Front-Line Therapy With Second-Generation Tyrosine Kinase Inhibitors in Patients With Early Chronic Phase Chronic Myeloid Leukemia: What Is the Optimal Response?JABBOUR, Elias; KANTARJIAN, Hagop M; O'BRIEN, Susan et al.Journal of clinical oncology. 2011, Vol 29, Num 32, pp 4260-4265, issn 0732-183X, 6 p.Article

Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemiaRAVANDI, Farhad; O'BRIEN, Susan; LUTHRA, Rajyalakshmi et al.Blood. 2011, Vol 118, Num 14, pp 3818-3823, issn 0006-4971, 6 p.Article

Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failureJABBOUR, Elias; KANTARJIAN, Hagop; O'BRIEN, Susan et al.Blood. 2011, Vol 117, Num 6, pp 1822-1827, issn 0006-4971, 6 p.Article

Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutationsJABBOUR, Elias; CORTES, Jorge; KANTARJIAN, Hagop et al.Blood. 2011, Vol 117, Num 13, pp 3641-3647, issn 0006-4971, 7 p.Article

The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitorsJABBOUR, Elias; KANTARJIAN, Hagop; O'BRIEN, Susan et al.Blood. 2011, Vol 118, Num 17, pp 4541-4546, issn 0006-4971, 6 p.Article